Gilead Fights For Viread Patent And Royalties In India
This article was originally published in PharmAsia News
Executive Summary
Gilead Sciences is challenging a decision in India refusing patent protection for its worldwide HIV blockbuster drug Viread (tenofovir)
You may also be interested in...
Relevant Pipeline Brings Gilead Closer to Direct Indian Presence
Long after it has established business links with Indian drug makers, Gilead Sciences is looking to set up its own India office. All these years, the US firm has stopped shy of a direct presence but the growing relevance of its drug pipeline to the local population now makes this a strategic imperative, say industry insiders.
A Closer Look: Gilead’s Viread Donation To China
Gilead’s decision to donate Viread to Chinese HIV patients came at a time when China was updating its compulsory license rules. The U.S. company may have also been thinking about the potential ramifications for hepatitis B, a much larger market in China.
China Compulsory Licensing Reg Opens Door For Generics Of Patented Drugs
Taking the lead from India’s recent compulsory license for Bayer’s Nexavar, China passes a compulsory license regulation that could allow generics on patented drugs.